What do systematic reviews say?

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in hyperkalaemia Range of compared with usual care (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.88 [0.77, 1.01]
  2 studies · 5054 participants
  Moderate

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

Angiotensin receptor neprilysin inhibitors (ARNIs) leads to lower all‐cause mortality (RR) Range of compared with usual care (high certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.97
  3 studies · 7663 participants
  High

Angiotensin receptor neprilysin inhibitors (ARNIs) vs usual care

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  118 participants
  High

Beta‐blockers vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 245 participants
  Very low

Beta‐blockers vs placebo or no treatment

Beta‐blockers showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (low certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.82 [0.67, 1]
  4 studies · 1105 participants
  Low

Beta‐blockers vs placebo or no treatment

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 93 participants
  Very low

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.9 [0.74, 1.11]
  3 studies · 4070 participants
  Moderate

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Mineralocorticoid receptor antagonists (MRAs) probably leads to lower heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.82 [0.69, 0.98]
  3 studies · 3714 participants
  Moderate

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Mineralocorticoid receptor antagonists (MRAs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 2.11 [1.77, 2.52]
  6 studies · 4291 participants
  High

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).

• Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
  RR 0.91 [0.78, 1.06]
  5 studies · 4207 participants
  Moderate

Stem cell therapy vs control

It is very uncertain whether stem cell therapy changes all‐cause mortality compared with control (very low certainty).

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  RR 0.84 [0.54, 1.31]
  7 studies · 361 participants
  Very low

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Low

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 155 participants
  Low

Stem cell therapy vs peripheral therapy with granulocyte colony‐stimulating factor

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 361 participants
  Very low

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 272 participants
  Very low

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 230 participants
  Very low

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 398 participants
  Low

Stem cell therapy vs control

• Stem cell therapy for dilated cardiomyopathy 2021 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported